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Clinical PerspectiveWhat Is New?Adherence to evidence‐based care was associated with improved outcomes in patients with ischemic stroke who participated in the large pragmatic trial HEADPOST (Head Positioning in Acute Stroke Trial).However, there was significant variation in the amount of evidence‐based care across regions, and few patients received the entire range (optimal treatment) of such performance indicators.What Are the Clinical Implications?There is considerable opportunity to increase the uptake of evidence‐based care in ischemic stroke to improve clinical outcomes from this serious condition.

Introduction {#jah34218-sec-0009}
============

Stroke is a major cause of death and disability, especially in low‐resource regions.[1](#jah34218-bib-0001){ref-type="ref"} Although considerable advances have been made in generating the evidence base that supports various treatments, particularly for acute ischemic stroke (AIS), their implementation is often limited by resource, organizational, and funding barriers in clinical practice.[2](#jah34218-bib-0002){ref-type="ref"} For example, acute stroke unit (ASU) care is one of the most cost‐effective treatments,[3](#jah34218-bib-0003){ref-type="ref"}, [4](#jah34218-bib-0004){ref-type="ref"}, [5](#jah34218-bib-0005){ref-type="ref"} but many hospitals around the world do not have such a service or only have it organized in a partial manner.[6](#jah34218-bib-0006){ref-type="ref"} Improvements in the delivery of stroke care can translate into better patient outcomes, but most "real‐life" quality‐of‐care evaluations are undertaken in well‐resourced hospitals located in high‐income countries and without necessarily considering both organizational and patient variables.[7](#jah34218-bib-0007){ref-type="ref"}, [8](#jah34218-bib-0008){ref-type="ref"} A better understanding of variations in the processes of care in relation to patient outcomes can help prioritize efforts toward improving the implementation of evidence, especially in low‐ and middle‐income countries.[9](#jah34218-bib-0009){ref-type="ref"}, [10](#jah34218-bib-0010){ref-type="ref"}

In a previous report, we identified large variations in the organization of stroke care (ie, staffing, protocols, and discharge planning) across hospitals in different countries in establishing the network for the international, multicenter HEADPOST (Head Positioning in Acute Stroke Trial).[11](#jah34218-bib-0011){ref-type="ref"} More research is needed on the impact of gaps in evidence‐based care in low‐ and middle‐income countries, where access to ASU care, let alone other therapies, is often limited.[12](#jah34218-bib-0012){ref-type="ref"} We aimed to determine the association between the use of recommended evidence‐based processes of stroke care and clinical outcomes for patients with AIS who participated in HEADPOST using analyses to account for hospital and patient characteristics.

Methods {#jah34218-sec-0010}
=======

The data that support the findings of this study are available through a formal protocol request from researchers to the Research Office of The George Institute Australia via the corresponding author.

Design {#jah34218-sec-0011}
------

HEADPOST was an international, multicenter, cluster‐randomized, crossover trial with centralized outcome assessment, the details of which are outlined elsewhere.[13](#jah34218-bib-0013){ref-type="ref"}, [14](#jah34218-bib-0014){ref-type="ref"} In brief, the trial used a pragmatic design with broad eligibility and assessment criteria, to facilitate the recruitment of 11 093 adult patients with a clinical diagnosis of acute stroke (AIS or intracerebral hemorrhage) to determine the effectiveness of lying flat (0°) compared with sitting up (≥30°) head positioning, applied within the first 24 hours of admission at 114 hospitals in 9 countries, during 2016 to 2017. Patients were eligible for inclusion in the trial if they were aged ≥18 years, presented to the emergency department or an inpatient service at a participating center, and received a clinical diagnosis of acute stroke. Patients were excluded if the local clinician‐investigator considered that the assigned head position could not be maintained consistently, if the confirmed diagnosis was a transient ischemic attack, or if the patient declined to participate in the trial. Patients were also excluded if there was a clear indication for, or contraindication to, either of the head positions.[13](#jah34218-bib-0013){ref-type="ref"} Local investigators were required to recruit a prespecified target (cluster) number of consecutive patients into an initial randomized head position that was implemented as a usual standard‐of‐care policy before the service was crossed over for the other randomized head position to be implemented as a similar standard‐of‐care policy. The protocol was approved by all regulatory authorities and ethics committees at participating hospitals. A senior executive officer at each hospital acted as a "guardian" (as part of the cluster‐randomized trial design) and provided consent at an institutional level for head positioning to be implemented as a "low‐risk intervention" to clusters of patients as part of routine care; written informed consent was subsequently obtained from patients (or their approved surrogates) for the collection of medical data and participation in follow‐up assessments. The corresponding author has full access to all the data in the study and takes responsibility for their integrity and the data analysis.

To assist the implementation of the intervention at each site, data were gathered on the organization of the hospital and in the wards involved in implementing the randomized interventions. After a baseline assessment that included collecting demographic, medical history, and clinical information on the severity of the neurological deficit, according to the National Institutes of Health Stroke Scale and vital signs, adherence to the allocated head position was monitored in patients over the subsequent 24 hours. Further follow‐up data were collected on the management of patients at the time of separation (day 7 or at hospital discharge, transfer, or death, if earlier) and all serious adverse events, including death, until 90 days. Appropriately trained outcome assessors in a central office, who were kept blind to the management of patients, used a script to conduct a telephone assessment of health and physical functioning at 90 days. The key clinical outcome was the degree of disability, according to the modified Rankin Scale (mRS) score.[15](#jah34218-bib-0015){ref-type="ref"} Main study results showed that disability outcomes after acute stroke did not differ significantly between patients assigned to a lying‐flat position for 24 hours and patients assigned to a sitting‐up position with the head elevated to at least 30° for 24 hours.[13](#jah34218-bib-0013){ref-type="ref"}

Statistical Analysis {#jah34218-sec-0012}
--------------------

Only patients with AIS were included in these analyses. Comparisons of categorical and continuous variables were assessed with the χ^2^ and Wilcoxon Mann‐Whitney rank sum tests, respectively. Univariable analyses were used to evaluate associations between patient characteristics and process‐of‐care indicators with 90‐day clinical outcomes. Multilevel logistic regression models were used to examine the associations between processes of care implemented in the first week (by day 7 or at discharge, if earlier) on good outcome (mRS score 0--2). The following processes of care were considered independent variables: (1) use of intravenous recombinant tPA (tissue‐type plasminogen activator) or endovascular clot retrieval in patients who presented at the hospital within 4.5 hours of symptom onset; (2) admission to an ASU; use of (3) antihypertensive, (4) antiplatelet, (5) statin, and (6) anticoagulation therapy in those with evidence of atrial fibrillation/flutter (AF); (7) receipt of a dysphagia screen and/or assessment before feeding was commenced; and (8) assessment by a physiotherapist in patients with residual disability (mRS score 3--5 on day 7). A composite variable of early "defect‐free" care (including the aforementioned 8 independent processes of care) was constructed to identify the proportion of eligible patients who received all applicable processes of care. A hierarchical mixed logistic regression with fixed period, fixed head position effect, random cluster, and random cluster‐period effects, plus the variable for evidence‐based care, was used as the base model. Three sequential models were constructed to adjust for other patient‐ and hospital‐level characteristic associations with patient outcomes. Variables were treated as independent variables. Association between defect‐free care and excellent outcome (90‐day mRS score 0--1) was also evaluated.

Consistency of treatment effect across prespecified subgroups (defined by age, sex, major country/region groupings, baseline National Institutes of Health Stroke Scale score, and pathologic subtype of AIS) was assessed by means of tests for interaction. Sensitivity analyses included the use of multiple imputation because \>10% of observations for mRS scores were missing at 90 days[16](#jah34218-bib-0016){ref-type="ref"} and exclusion of those who had died within the first 7 days after admission.

To analyze the association between patients' outcome and hospital characteristics, univariable analyses were performed using hierarchical mixed logistic regression models, as previously described, taking account of the cluster crossover study design. Multivariable analyses included adjustment for patient characteristics that had the potential to influence recovery: age, sex, history of hypertension, stroke, heart disease or diabetes mellitus, premorbid estimated mRS score, baseline National Institutes of Health Stroke Scale score, time from symptom onset to commencement of the intervention, and country. Adjustment variables were selected for potential clinical significance as well as statistical significance on initial univariable analyses. Data are reported with 2‐sided *P* values, without adjustment for multiple comparisons, and as odds ratios with 95% CIs. All analyses were undertaken with SAS software, version 9.3 (SAS Institute).

Role of the Funding Source {#jah34218-sec-0013}
--------------------------

The study sponsor was not involved in the study design or collection, analysis, and interpretation of data; and had no role in the writing of this report or in the decision to submit the manuscript for publication.

Results {#jah34218-sec-0014}
=======

There were 9485 patients with AIS included in analyses (Figure [1](#jah34218-fig-0001){ref-type="fig"}). Table [1](#jah34218-tbl-0001){ref-type="table"} shows that patients with AIS who received defect‐free stroke care had more risk factors, lower levels of premorbid disability, and greater baseline neurological impairment, compared with those who did not receive defect‐free stroke care. Defect‐free care was more frequent in hospitals in Australia and the United Kingdom, in those with lower numbers of stroke admissions per annum, in nonacademic hospitals, and in those where specific protocols for stroke care were in place and where multidisciplinary teams were involved in usual care.

![Patient flow diagram.](JAH3-8-e012640-g001){#jah34218-fig-0001}

###### 

Characteristics of Ischemic Stroke Patients and Hospitals, Stratified by Receipt of "Defect‐Free" Evidence‐Based Care

  Variable                                    Defect‐Free Care                               
  ------------------------------------------- ------------------ ------------- ------------- ---------
  Patients                                                                                   
  Age, y                                      69 (59--79)        72 (63--81)   68 (59--78)   0.999
  Men                                         5759 (60.7)        826 (57.2)    4933 (61.4)   0.914
  Hypertension                                6141 (64.9)        1154 (80.0)   4987 (62.2)   \<0.001
  Prior stroke                                2258 (23.9)        280 (19.4)    1978 (24.7)   0.826
  Coronary artery disease                     1339 (14.2)        250 (17.4)    1089 (13.6)   0.002
  Atrial fibrillation                         1059 (11.2)        106 (7.4)     953 (11.9)    \<0.001
  Heart failure                               358 (3.8)          57 (4.0)      301 (3.8)     0.184
  Diabetes mellitus                           2354 (24.9)        451 (31.3)    1903 (23.7)   \<0.001
  Tobacco use                                 1924 (20.5)        241 (16.8)    1683 (21.2)   0.917
  Aspirin or other antiplatelet use           5182 (54.7)        677 (46.9)    4505 (56.1)   \<0.001
  Anticoagulant use                           824 (8.7)          86 (6.0)      738 (9.2)     \<0.001
  Premorbid function on the mRS                                                              
  0 (No symptoms)                             5800 (61.3)        968 (67.1)    4832 (60.2)   0.012
  1 (No significant disability)               1691 (17.9)        214 (14.8)    1477 (18.4)   ...
  2 (Slight disability)                       998 (10.5)         125 (8.7)     873 (10.9)    ...
  3 (Moderate disability)                     598 (6.3)          93 (6.4)      505 (6.3)     ...
  4 (Moderate/severe disability)              306 (3.2)          32 (2.2)      274 (3.4)     ...
  5 (Severe disability)                       76 (0.8)           11 (0.8)      65 (0.8)      ...
  Admission NIHSS score                       4 (2--8)           4 (2--8)      4 (2--8)      \<0.001
  Symptom onset to intervention, h            14 (5--37)         16 (7--33)    14 (5--39)    \<0.001
  Initial head position lying flat            4532 (47.8)        685 (47.4)    3847 (47.8)   0.770
  Region of recruitment                                                                      
  Australia/United Kingdom                    3850 (40.6)        1001 (69.3)   2849 (35.4)   \<0.001
  China, including Taiwan                     4178 (44.0)        171 (11.8)    4007 (49.8)   ...
  India and Sri Lanka                         658 (6.9)          151 (10.4)    507 (6.3)     ...
  South America                               799 (8.4)          122 (8.4)     677 (8.4)     ...
  Hospitals                                                                                  
  No. of stroke patients annually                                                            
  \<500                                       2252 (24.1)        442 (30.6)    1810 (22.9)   0.010
  500--1000                                   3642 (39.0)        673 (46.6)    2969 (37.6)   ...
  \>1000                                      3446 (36.9)        330 (22.8)    3116 (39.5)   ...
  Academic teaching hospital                  8094 (86.5)        1112 (77.0)   6982 (88.3)   0.007
  Pathway for stroke care                     8491 (90.8)        1416 (98.0)   7075 (89.5)   \<0.001
  Protocols for fever/blood glucose/swallow   7043 (75.3)        1088 (75.3)   5955 (75.3)   0.899
  ED protocols                                8847 (94.6)        1309 (90.6)   7538 (95.3)   0.256
  Multidisciplinary teams                     5561 (59.5)        1170 (81.0)   4391 (55.5)   \<0.001
  Endovascular clot retrieval                 5305 (57.4)        685 (48.8)    4620 (58.9)   0.042

Data are given as number (percentage) or median (interquartile range). ED indicates emergency department; mRS modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale.

*P* values from unadjusted hierarchical mixed logistic regression model, with link function being logit with fixed period, fixed head position effect, random cluster, and random cluster‐period effects.

Table [2](#jah34218-tbl-0002){ref-type="table"} shows the results of multilevel modeling: use of antiplatelets, use of statins, dysphagia screen, and physiotherapy assessment were associated with better clinical outcome. The use of standard reperfusion treatment (recombinant tPA or endovascular clot retrieval within the first 4.5 hours of symptoms onset) was also associated with better disability‐free survival after adjusting for patient and hospital characteristics. Early implementation of all stroke care eligible processes of care was associated with greater likelihood of good clinical outcome (odds ratio, 1.40; 95% CI, 1.18--1.65). When the outcome considered was mRS score 0 to 1, the association between early implementation of defect‐free care and greater likelihood of excellent outcome (mRS score 0--1) remained significant (odds ratio, 1.22; 95% CI, 1.04--1.43). These results were further confirmed in sensitivity analyses with multiple imputations for missing primary outcome data (Table [S1](#jah34218-sup-0001){ref-type="supplementary-material"}) by excluding patients with early death (Table [2](#jah34218-tbl-0002){ref-type="table"}), and after excluding patients who received reperfusion therapy and anticoagulation for AF (Table [2](#jah34218-tbl-0002){ref-type="table"}). In terms of survival at 90 days, multilevel modeling showed that use of all processes of care was associated with better survival (odds ratio, 2.23; 95% CI, 1.62--3.09) (Table [S2](#jah34218-sup-0001){ref-type="supplementary-material"}).

###### 

Evidence‐Based AIS Processes of Care and Good Outcome, in Various Models

  Variable                                                                Good Outcome   Total         Unadjusted          Model 1   Model 2             Model 3                                                     
  ----------------------------------------------------------------------- -------------- ------------- ------------------- --------- ------------------- --------- ------------------- --------- ------------------- ---------
  Reperfusion therapy (n=3093)                                            591 (34.2)     1051 (34.0)   1.06 (0.91--1.25)   0.454     0.87 (0.73--1.04)   0.129     1.39 (1.13--1.71)   0.002     1.40 (1.14--1.73)   0.001
  ASU admission                                                           2633 (51.5)    4723 (56.3)   0.77 (0.65--0.91)   0.003     1.01 (0.82--1.25)   0.932     1.01 (0.81--1.25)   0.940     1.05 (0.84--1.32)   0.669
  Antihypertensive therapy                                                2771 (54.2)    4725 (56.4)   0.89 (0.81--0.98)   0.023     1.06 (0.96--1.18)   0.255     1.08 (0.95--1.24)   0.221     1.09 (0.95--1.24)   0.208
  Antiplatelet therapy                                                    4975 (97.3)    8063 (96.2)   1.98 (1.56--2.50)   \<0.001   1.91 (1.49--2.47)   \<0.001   1.50 (1.12--2.00)   0.007     1.52 (1.13--2.03)   0.006
  Statin therapy                                                          4390 (85.9)    6960 (83.0)   1.64 (1.45--1.87)   \<0.001   1.47 (1.28--1.69)   \<0.001   1.27 (1.09--1.48)   0.003     1.26 (1.08--1.47)   0.004
  Anticoagulation in AF (n=1203)[a](#jah34218-note-0006){ref-type="fn"}   259 (49.7)     574 (47.7)    1.14 (0.89--1.45)   0.293     ...                           ...                           ...                 ...
  Swallow assessment                                                      3916 (76.6)    6279 (74.9)   1.47 (1.30--1.67)   \<0.001   1.38 (1.20--1.58)   \<0.001   1.26 (1.09--1.46)   0.002     1.26 (1.08--1.47)   0.003
  Physiotherapy in disabled patients (n=3073)                             645 (72.5)     2194 (71.4)   1.20 (0.96--1.50)   0.102     1.53 (1.17--1.99)   0.002     1.50 (1.14--1.97)   0.004     1.47 (1.11--1.95)   0.008
  "Defect‐free" stroke care                                               770 (15.1)     1229 (14.7)   1.45 (1.26--1.67)   \<0.001   1.48 (1.27--1.71)   \<0.001   1.40 (1.19--1.65)   \<0.001   1.40 (1.18--1.65)   \<0.001
  Defect‐free stroke care (without reperfusion/anticoagulation)           1146 (22.4)    1941 (23.2)   1.21 (1.07--1.37)   0.002     1.36 (1.19--1.56)   \<0.001   1.28 (1.10--1.49)   0.002     1.28 (1.10--1.49)   0.002
  Defect‐free stroke care (only survivors \>7 d) (n=8265)                 770 (15.1)     1224 (14.8)   1.39 (1.21--1.60)   \<0.001   1.42 (1.22--1.65)   \<0.001   1.38 (1.17--1.63)   \<0.001   1.38 (1.16--1.63)   \<0.001

Analyses used multilevel logistic regression models with fixed period, fixed head position effect, random cluster, and random cluster‐period effects. Model 1: adjusted for country, prestroke modified Rankin Scale score, age, and sex. Model 2: further adjustment for baseline National Institutes of Health Stroke Scale score; history of stroke, heart disease, diabetes mellitus, and hypertension; and time from stroke onset to intervention. Model 3: further adjustment for number of patients with stroke admitted annually, availability of a multidisciplinary team, hospital status (academic or not), use of pathway or service organization for stroke care, and availability of endovascular treatment. Good outcome indicates modified Rankin Scale score 0 to 2. AF indicates atrial fibrillation; AIS, acute ischemic stroke; ASU, acute stroke unit; OR, odds ratio.

Result models not shown because of failure to converge caused by low numbers.

Overall, use of the AIS processes of care was low (1445/9485, 15.2%) and varied widely across regions, being highest in Australia/United Kingdom (1001/3850, 26.0%) and India/Sri Lanka (151/658, 22.9%), intermediate in South America (122/691, 15.2%), and lowest in China (171/4178, 4.1%) (*P*\<0.001) (Table [S3](#jah34218-sup-0001){ref-type="supplementary-material"}). Those components with the greatest regional differences were ASU admission, use of antihypertensive therapy, anticoagulation for AF, and physiotherapy assessment. There was consistency in the beneficial associations across patient subgroups (Figures [2](#jah34218-fig-0002){ref-type="fig"} and [3](#jah34218-fig-0003){ref-type="fig"}), but no hospital characteristic was independently predictive of clinical outcome (Table [S4](#jah34218-sup-0001){ref-type="supplementary-material"}).

!["Defect‐free" stroke care and good outcome (modified Rankin Scale \[mRS\] scores 0--2) at 90 days, by subgroups. AIS indicates acute ischemic stroke; NIHSS, National Institutes of Health Stroke Scale; OR, odds ratio.](JAH3-8-e012640-g002){#jah34218-fig-0002}

![Impact in 90‐day mortality of "defect‐free" stroke care in different prespecified subgroups. AIS indicates acute ischemic stroke; NIHSS, National Institutes of Health Stroke Scale; OR, odds ratio.](JAH3-8-e012640-g003){#jah34218-fig-0003}

Discussion {#jah34218-sec-0015}
==========

These secondary analyses of a large international clinical trial have 2 major findings. First, data show that the implementation of guideline‐recommended AIS processes of care is associated with clear beneficial clinical outcome, including a dramatic halving in the risk of death within 90 days, even after accounting for a range of confounding variables. Second, overall use of defect‐free stroke care was low, and there was considerable regional variation, especially across several components, including the use of ASU care. Although the organization of services is important for delivering efficient and effective stroke care, we were unable to identify a specific hospital characteristic that was independently associated with clinical outcome; patient‐level characteristics were the main driver of clinical outcome.

Various stroke quality assessment and improvement programs exist around the world. In the United States, for example, the Centers for Disease Control and Prevention monitors adherence to 10 quality‐of‐care measures in hospitals across 7 states through the Paul Coverdell National Acute Stroke Registry, where patients who received the best quality of care have been shown to have an increased chance of long‐term survival.[8](#jah34218-bib-0008){ref-type="ref"} Quality of care and process improvement have also been presented in numerous publications from the American Heart Association\'s Get With The Guidelines program.[17](#jah34218-bib-0017){ref-type="ref"} Similar initiatives have been developed in Australia and the United Kingdom,[7](#jah34218-bib-0007){ref-type="ref"}, [18](#jah34218-bib-0018){ref-type="ref"}, [19](#jah34218-bib-0019){ref-type="ref"} but there are few available in developing countries.[20](#jah34218-bib-0020){ref-type="ref"} In keeping with our findings of the cumulative benefit on outcomes from multiple processes of care, data from the Australian Stroke Clinical Registry have shown that patients who received 3 processes of care (stroke unit care, discharged on antihypertensive agents, and discharged with a care plan) had a 70% reduced hazard of death at 180 days.[18](#jah34218-bib-0018){ref-type="ref"}

Within the various processes of care analyzed, reperfusion treatment and ASU care showed the greatest variations across the participating countries in our study, despite being recognized as those with the largest benefit. As a time‐critical treatment, use of intravenous thrombolysis is often restricted by local barriers, such as system networks and patient awareness of disease, resulting in early emergency consultation. For example, fewer patients receive recombinant tPA when arriving within 4 hours of symptom onset (39%),[21](#jah34218-bib-0021){ref-type="ref"} compared with those arriving within 2 hours (88%).[22](#jah34218-bib-0022){ref-type="ref"} Another consideration to be made is about stroke care performance and admission volume because our findings are opposed to the usual assumption that practice improves processes of care. This might have been related to overwhelming clinical volumes in larger hospitals, mostly from the Asian region.

We recognize that the definitions and timing of defect‐free stroke care treatments may vary,[21](#jah34218-bib-0021){ref-type="ref"}, [22](#jah34218-bib-0022){ref-type="ref"} as is the case for anticoagulation in those with AF and the initiation of antihypertensive treatment after AIS. Although current guidelines recommend initiation of anticoagulation within 2 weeks of a cardioembolic stroke, except for patients with large infarcts or other risk factors for hemorrhage,[23](#jah34218-bib-0023){ref-type="ref"} timing for treatment initiation after the onset of AIS presents high variability in practice. On the other hand, there is global consensus on the use of blood pressure--lowering treatment in patient candidates for acute reperfusion therapy and in patients not receiving reperfusion therapy but with severe hypertension.[24](#jah34218-bib-0024){ref-type="ref"} Early commencement of antihypertensive therapy in patients with milder hypertension is subjected to more debate, although it appears to be safe and reasonable to improve long‐term blood pressure control, unless contraindicated. Although we have shown that the initiation of anticoagulation and blood pressure lowering within 7 days was related to higher survival after AIS, there is the potential for this to reflect indication bias, whereby the treating clinician could have commenced the treatment earlier in those considered at low risk of complications and clinically stable.

Even after excluding the use of thrombolysis and thrombectomy, which can be more complex and dependent on specific time frames, and anticoagulation for AF, where early initiation is debatable, we have shown that defect‐free treatment was only applied in approximately one fifth of patients from this international cohort, revealing an alarming gap in guideline‐directed treatment. Direct comparison with other studies is limited by use of different criteria; however, an audit of UK hospitals revealed 46% of patients with AIS received good quality treatment in the first 72 hours.[19](#jah34218-bib-0019){ref-type="ref"} The latter considered different quality criteria, including brain scan; early evaluation by stroke consultant or associate specialist, nurse, and therapists; swallow evaluation; admission to stroke unit; antiplatelet use; and fluid/nutrition. When individual processes of care are compared, results are similar to our findings on swallow assessment, ASU, and antiplatelets use.[19](#jah34218-bib-0019){ref-type="ref"} In a recent report from INTERSTROKE (a case‐control study of the global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries), use of thrombolysis, antiplatelets, and statins was lower in comparison to our results, and higher for blood pressure lowering.[12](#jah34218-bib-0012){ref-type="ref"} Moreover, the authors showed that patients enrolled from hospitals in low‐ and middle‐income countries had poorer access to investigations, treatments, and services compared with those enrolled from hospitals in high‐income countries. In line with our results, these patients had worse clinical outcomes, which could only be partly explained by the inclusion of patients with more severe stroke. These findings highlight the importance of widespread implementation of stroke processes of care, particularly across low‐resource areas, where they are still scarce.

As stroke is a national priority in China, the central government has initiated a program of quality improvement strategies that include screening for high‐risk individuals in the community, process‐of‐care performance measures, and organizational development to improve stroke care.[25](#jah34218-bib-0025){ref-type="ref"} Multifaceted initiatives have been shown to improve adherence to performance measures in Chinese hospitals, but were not able to show significant change in the defect‐free stroke care.[26](#jah34218-bib-0026){ref-type="ref"} Accordingly, our data reemphasize the importance of quality improvement initiatives in China.

To our knowledge, this is the first study to assess the impact of using multiple evidence‐based stroke care processes on clinical outcomes in a large multinational cohort of patients. HEADPOST was a clinical trial with broad inclusion criteria, allowing the participation of a wide range of patients; and the analyses herein presented were strengthened by the use of multilevel modeling to account for patient‐ and hospital‐level variables. Inevitably, though, these secondary analyses of nonrandomized processes of care are limited by the potential for chance associations and residual confounding, as well as broad assumption of patient eligibility for different process of care. Interactions between different stroke care interventions were not explored, leading to possible risk of confounding by indication. Because the main study had 10% of missing primary outcome data in mRS score, the decision to use imputation for missing mRS scores is also to be acknowledged as a limitation of the study.

In summary, in this study, we have shown, among eligible patients with AIS, that those who received evidence‐based processes of care had better outcomes, but the overall uptake of the suite of therapies was low across a multinational population. Strategies to facilitate implementation of evidence‐based stroke care are needed, particularly in low‐resource regions.

Appendix {#jah34218-sec-0016}
========
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